These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27173155)

  • 41. Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
    de Peuter OR; Verberne HJ; Kok WE; van den Bogaard B; Schaap MC; Nieuwland R; Meijers JC; Somsen GA; Bakx A; Kamphuisen PW
    J Nucl Med; 2013 Oct; 54(10):1733-9. PubMed ID: 23970363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The sympathetic nervous system and pathophysiology of congestive heart failure.
    Farmer J
    Postgrad Med; 2005 Dec; 118(6 Suppl Beta-Blockers):6-11. PubMed ID: 19667705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Beta blockers in therapy of chronic heart failure].
    Hoffman J; Grimm W; Maisch B
    Herz; 2002 Mar; 27(2):150-65. PubMed ID: 12025460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nebivolol for the treatment of heart failure.
    Riva N; Lip GY
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1733-46. PubMed ID: 21980961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure.
    Francis GS
    Am Heart J; 1989 Sep; 118(3):642-8. PubMed ID: 2570521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure poverty in the presence of plenty.
    Haider N; Baliga RR; Chandrashekhar Y; Narula J
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):71-5. PubMed ID: 20129534
    [No Abstract]   [Full Text] [Related]  

  • 48. beta-Blocker therapy for congestive heart failure: clinical considerations.
    Kamath SA; Yancy CW
    Postgrad Med; 2005 Dec; 118(6 Suppl Beta-Blockers):12-20. PubMed ID: 19667706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nebivolol in chronic heart failure: current evidence and future perspectives.
    Lipsic E; van Veldhuisen DJ
    Expert Opin Pharmacother; 2010 Apr; 11(6):983-92. PubMed ID: 20307222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The background of the MERIT-HF trial.
    Dietz R; Osterziel KJ; Willenbrock R; Hänlein D; von Harsdorf R
    Basic Res Cardiol; 2000; 95 Suppl 1():I84-9. PubMed ID: 11192360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential use of beta(3)-adrenoceptor antagonists in heart failure therapy.
    Moniotte S; Balligand JL
    Cardiovasc Drug Rev; 2002; 20(1):19-26. PubMed ID: 12070531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy.
    Feldman AM; Bristow MR
    Cardiology; 1990; 77 Suppl 1():1-32. PubMed ID: 1970755
    [No Abstract]   [Full Text] [Related]  

  • 53. Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence.
    Giagulli VA; Guastamacchia E; Licchelli B; Triggiani V
    Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):22-30. PubMed ID: 27981914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits of beta-blocker therapy for heart failure: weighing the evidence.
    Goldstein S
    Arch Intern Med; 2002 Mar; 162(6):641-8. PubMed ID: 11911717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure.
    Floras JS
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):72A-84A. PubMed ID: 8376699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of atrial fibrillation ablation on cardiac sympathetic nervous system in patients with and without heart failure.
    Masuda M; Yamada T; Mizuno H; Minamiguchi H; Konishi S; Ohtani T; Yamaguchi O; Okuyama Y; Uematsu M; Sakata Y
    Int J Cardiol; 2015 Nov; 199():65-70. PubMed ID: 26186633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of the myocardial redox state by vagal nerve stimulation after experimental myocardial infarction.
    Tsutsumi T; Ide T; Yamato M; Kudou W; Andou M; Hirooka Y; Utsumi H; Tsutsui H; Sunagawa K
    Cardiovasc Res; 2008 Mar; 77(4):713-21. PubMed ID: 18065771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Adrenergic beta inhibitors in heart insufficiency: which and when?].
    Coutinho J
    Rev Port Cardiol; 2001 Mar; 20 Suppl 3():17-25. PubMed ID: 11409070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The neuroendocrine and sympathetic nervous system in congestive heart failure.
    Ferrari R; Ceconi C; Curello S; Visioli O
    Eur Heart J; 1998 Jun; 19 Suppl F():F45-51. PubMed ID: 9651735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurocognitive Disorders in Heart Failure: Novel Pathophysiological Mechanisms Underpinning Memory Loss and Learning Impairment.
    Toledo C; Andrade DC; Díaz HS; Inestrosa NC; Del Rio R
    Mol Neurobiol; 2019 Dec; 56(12):8035-8051. PubMed ID: 31165973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.